Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Non-Current Debt (2016 - 2017)

Bone Biologics has reported Non-Current Debt over the past 3 years, most recently at $8.2 million for Q4 2017.

  • Quarterly Non-Current Debt rose 8.81% to $8.2 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2017, up 8.81% year-over-year, with the annual reading at $8.2 million for FY2017, 8.81% up from the prior year.
  • Non-Current Debt was $8.2 million for Q4 2017 at Bone Biologics, up from $7.2 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $8.2 million in Q4 2017 and troughed at $5.1 million in Q4 2015.
  • The 3-year median for Non-Current Debt is $6.6 million (2017), against an average of $6.5 million.
  • Year-over-year, Non-Current Debt surged 48.8% in 2016 and then rose 8.81% in 2017.
  • A 3-year view of Non-Current Debt shows it stood at $5.1 million in 2015, then soared by 48.8% to $7.6 million in 2016, then rose by 8.81% to $8.2 million in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Non-Current Debt are $8.2 million (Q4 2017), $7.2 million (Q3 2017), and $6.9 million (Q2 2017).